Dosimetric Vergelijking van Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiotherapie for Localized Prostaatkanker: Post Hoc Analyse of a Fase 3-Trial

The MIRAGE (Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer) trial (NCT04384770) showed that aggressive planning target volume (PTV) margin reduction, achieved by leveraging the advanced image-guidance of magnetic resonance imaging guided radiation therapy, led to lower toxicity after stereotactic body radiation therapy (SBRT) to the prostate compared with computed tomography guided SBRT (CTgSBRT) with a standard PTV margin. It is unknown whether the dosimetric benefit of reducing PTV margins alone—independent of the other components of advanced image guided radiation therapy that allowed margin reduction—would be predicted to replicate this decrease in toxicity.